Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Gains Global Rights to Topical Biologic for Psoriasis

publication date: May 30, 2018

Zai Lab of Shanghai acquired global rights to a topical biologic treatment for inflammatory conditions developed by Crescendo Biologics (Cambridge, UK). Zai Lab will have rights to develop, commercialize and manufacture the innovative antibody V_H domain therapeutic, focusing initially on psoriasis. Crescendo received an upfront cash payment and will be eligible for development, regulatory, and commercial milestones for multiple indications, plus royalties. Zai expects to file an IND for the therapeutic candidate to begin clinical trials in psoriasis in 2019. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.